Towards the Fifth Pillar for the Treatment of Heart Failure with Reduced Ejection Fraction: Vericiguat in Older and Complex Patients.
Journal
American journal of cardiovascular drugs : drugs, devices, and other interventions
ISSN: 1179-187X
Titre abrégé: Am J Cardiovasc Drugs
Pays: New Zealand
ID NLM: 100967755
Informations de publication
Date de publication:
10 Jun 2024
10 Jun 2024
Historique:
accepted:
08
05
2024
medline:
10
6
2024
pubmed:
10
6
2024
entrez:
10
6
2024
Statut:
aheadofprint
Résumé
Heart failure with reduced ejection fraction (HFrEF) represents an emerging epidemic, particularly affecting frail, older, and multimorbid patients. Current therapy for the management of HFrEF includes four different classes of disease-modifying drugs, commonly referred to as 'four pillars', which target the neurohormonal system that is overactivated in HF and contributes to its progression. These classes of drugs include β-blockers, inhibitors of the renin-angiotensin-aldosterone system, mineralocorticoid receptor antagonists, and sodium-glucose co-transporter-2 (SGLT2) inhibitors. Unfortunately, these agents cannot be administered as frequently as needed to older patients because of poor tolerability and comorbidities. In addition, although these drugs have dramatically increased the survival expectations of patients with HF, their residual risk of rehospitalization and death at 5 years remains considerable. Vericiguat, a soluble guanylate cyclase (sGC) stimulator, was reported to exert beneficial effects in patients with worsening HF, including older subjects, reducing the rate of both hospitalizations and deaths, with limited adverse effects and drug interaction. In this narrative review, we present the current state of art on vericiguat, with a particular focus on elderly and frail patients.
Identifiants
pubmed: 38856965
doi: 10.1007/s40256-024-00652-6
pii: 10.1007/s40256-024-00652-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726. https://doi.org/10.1093/eurheartj/ehab368 .
doi: 10.1093/eurheartj/ehab368
pubmed: 34447992
Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J. 1999;137(2):352–60. https://doi.org/10.1053/hj.1999.v137.95495 .
doi: 10.1053/hj.1999.v137.95495
pubmed: 9924171
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Rev Esp Cardiol (Engl Ed). 2022;75(6):523. https://doi.org/10.1016/j.rec.2022.05.005 .
doi: 10.1016/j.rec.2022.05.005
pubmed: 35636830
Dovjak P. Polypharmacy in elderly people. Wien Med Wochenschr. 2022;172(5–6):109–13. https://doi.org/10.1007/s10354-021-00903-0 .
doi: 10.1007/s10354-021-00903-0
pubmed: 35006518
Cacciatore S, Martone AM, Landi F, Tosato M. Acute coronary syndrome in older adults: an update from the 2022 Scientific Statement by the American Heart Association. Heart Vessels Transplant. 2023;7(1):7–10. https://doi.org/10.24969/hvt.2023.367 .
doi: 10.24969/hvt.2023.367
Greene SJ, Bauersachs J, Brugts JJ, et al. Management of worsening heart failure with reduced ejection fraction: JACC focus seminar 3/3. J Am Coll Cardiol. 2023;82(6):559–71. https://doi.org/10.1016/j.jacc.2023.04.057 .
doi: 10.1016/j.jacc.2023.04.057
pubmed: 37532426
D’Amato A, Prosperi S, Severino P, et al. Current approaches to worsening heart failure: pathophysiological and molecular insights. Int J Mol Sci. 2024. https://doi.org/10.3390/ijms25031574 .
doi: 10.3390/ijms25031574
pubmed: 38791387
pmcid: 11120766
Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400(10367):1938–52. https://doi.org/10.1016/S0140-6736(22)02076-1 .
doi: 10.1016/S0140-6736(22)02076-1
pubmed: 36356631
Chiles R, Al-Horani RA. Vericiguat: a new hope for heart failure patients. Cardiovasc Ther. 2022;2022:1554875. https://doi.org/10.1155/2022/1554875 .
doi: 10.1155/2022/1554875
pubmed: 36618548
pmcid: 9789902
Gheorghiade M, Marti CN, Sabbah HN, et al. Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail Rev. 2013;18(2):123–34. https://doi.org/10.1007/s10741-012-9323-1 .
doi: 10.1007/s10741-012-9323-1
pubmed: 22622468
Campbell N, Kalabalik-Hoganson J, Frey K. Vericiguat: a novel oral soluble guanylate cyclase stimulator for the treatment of heart failure. Ann Pharmacother. 2022;56(5):600–8. https://doi.org/10.1177/10600280211041384 .
doi: 10.1177/10600280211041384
pubmed: 34431706
Gupta R, Lin M, Maitz T, et al. Vericiguat: a novel soluble guanylate cyclase stimulator for use in patients with heart failure. Cardiol Rev. 2023;31(2):87–92. https://doi.org/10.1097/CRD.0000000000000431 .
doi: 10.1097/CRD.0000000000000431
pubmed: 35609251
Coats AJS, Tolppanen H. Drug treatment of heart failure with reduced ejection fraction: defining the role of vericiguat. Drugs. 2021;81(14):1599–604. https://doi.org/10.1007/s40265-021-01586-y .
doi: 10.1007/s40265-021-01586-y
pubmed: 34478114
Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart failure with reduced ejection fraction: a review. JAMA. 2020;324(5):488–504. https://doi.org/10.1001/jama.2020.10262 .
doi: 10.1001/jama.2020.10262
pubmed: 32749493
Vannuccini F, Campora A, Barilli M, Palazzuoli A. Vericiguat in heart failure: characteristics, scientific evidence and potential clinical applications. Biomedicines. 2022. https://doi.org/10.3390/biomedicines10102471 .
doi: 10.3390/biomedicines10102471
pubmed: 36289733
pmcid: 9598881
Munzel T, Gori T, Bruno RM, Taddei S. Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J. 2010;31(22):2741–8. https://doi.org/10.1093/eurheartj/ehq396 .
doi: 10.1093/eurheartj/ehq396
pubmed: 20974801
Ghofrani HA, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319–29. https://doi.org/10.1056/NEJMoa1209657 .
doi: 10.1056/NEJMoa1209657
pubmed: 23883377
European Medicines Agency. VERQUVO® (vericiguat): EU summary of product characteristics. Amsterdam: European Medicines Agency; 2021.
Di Fusco SA, Alonzo A, Aimo A, et al. ANMCO Position paper: Vericiguat use in heart failure: from evidence to place in therapy [in Italian]. G Ital Cardiol (Rome). 2023;24(4):323–31. https://doi.org/10.1714/4004.39824 .
doi: 10.1714/4004.39824
pubmed: 36971177
Rao VN, Diez J, Gustafsson F, et al. Practical patient care considerations with use of vericiguat after worsening heart failure events. J Card Fail. 2023;29(3):389–402. https://doi.org/10.1016/j.cardfail.2022.10.431 .
doi: 10.1016/j.cardfail.2022.10.431
pubmed: 36529314
Lam CSP, Mulder H, Lopatin Y, et al. Blood pressure and safety events with vericiguat in the VICTORIA Trial. J Am Heart Assoc. 2021;10(22): e021094. https://doi.org/10.1161/JAHA.121.021094 .
doi: 10.1161/JAHA.121.021094
pubmed: 34743540
pmcid: 8751950
Ezekowitz JA, Zheng Y, Cohen-Solal A, et al. Hemoglobin and clinical outcomes in the vericiguat global study in patients with heart failure and reduced ejection fraction (VICTORIA). Circulation. 2021;144(18):1489–99. https://doi.org/10.1161/CIRCULATIONAHA.121.056797 .
doi: 10.1161/CIRCULATIONAHA.121.056797
pubmed: 34432985
Voors AA, Mulder H, Reyes E, et al. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. Eur J Heart Fail. 2021;23(8):1313–21. https://doi.org/10.1002/ejhf.2221 .
doi: 10.1002/ejhf.2221
pubmed: 33999486
Senni M, Alemayehu WG, Sim D, et al. Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial. Eur J Heart Fail. 2022;24(9):1614–22. https://doi.org/10.1002/ejhf.2608 .
doi: 10.1002/ejhf.2608
pubmed: 35791083
Khan MS, Xu H, Fonarow GC, et al. Applicability of vericiguat to patients hospitalized for heart failure in the United States. JACC Heart Fail. 2023;11(2):211–23. https://doi.org/10.1016/j.jchf.2022.11.007 .
doi: 10.1016/j.jchf.2022.11.007
pubmed: 36754528
pmcid: 11045268
Kerwagen F, Ohlmeier C, Evers T, et al. Real-world characteristics and use patterns of patients treated with vericiguat: a nationwide longitudinal cohort study in Germany. Eur J Clin Pharmacol. 2024;80(6):931–40. https://doi.org/10.1007/s00228-024-03654-0 .
doi: 10.1007/s00228-024-03654-0
pubmed: 38472389
pmcid: 11098883
Ezekowitz JA, McMullan CJ, Westerhout CM, et al. Background medical therapy and clinical outcomes from the VICTORIA Trial. Circ Heart Fail. 2023;16(9): e010599. https://doi.org/10.1161/CIRCHEARTFAILURE.123.010599 .
doi: 10.1161/CIRCHEARTFAILURE.123.010599
pubmed: 37417824
Evora PR, Evora PM, Celotto AC, Rodrigues AJ, Joviliano EE. Cardiovascular therapeutics targets on the NO-sGC-cGMP signaling pathway: a critical overview. Curr Drug Targets. 2012;13(9):1207–14. https://doi.org/10.2174/138945012802002348 .
doi: 10.2174/138945012802002348
pubmed: 22716077
Triposkiadis F, Xanthopoulos A, Skoularigis J, Starling RC. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure. Heart Fail Rev. 2022;27(6):1991–2003. https://doi.org/10.1007/s10741-022-10239-5 .
doi: 10.1007/s10741-022-10239-5
pubmed: 35437713
Premer C, Kanelidis AJ, Hare JM, Schulman IH. Rethinking endothelial dysfunction as a crucial target in fighting heart failure. Mayo Clin Proc Innov Qual Outcomes. 2019;3(1):1–13. https://doi.org/10.1016/j.mayocpiqo.2018.12.006 .
doi: 10.1016/j.mayocpiqo.2018.12.006
pubmed: 30899903
pmcid: 6408687
Stasch JP, Schlossmann J, Hocher B. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence. Curr Opin Pharmacol. 2015;21:95–104. https://doi.org/10.1016/j.coph.2014.12.014 .
doi: 10.1016/j.coph.2014.12.014
pubmed: 25645316
McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077 .
doi: 10.1056/NEJMoa1409077
pubmed: 25176015
McDonagh TA, Metra M, Adamo M, et al. 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627–39. https://doi.org/10.1093/eurheartj/ehad195 .
doi: 10.1093/eurheartj/ehad195
pubmed: 37622666
Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883–93. https://doi.org/10.1056/NEJMoa1915928 .
doi: 10.1056/NEJMoa1915928
pubmed: 32222134
Kaplinsky E, Perrone S, Barbagelata A. Emerging concepts in heart failure management and treatment: focus on vericiguat. Drugs Context. 2023. https://doi.org/10.7573/dic.2022-5-5 .
doi: 10.7573/dic.2022-5-5
pubmed: 36660017
pmcid: 9828879
McMurray JJV, DeMets DL, Inzucchi SE, et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019;21(5):665–75. https://doi.org/10.1002/ejhf.1432 .
doi: 10.1002/ejhf.1432
pubmed: 30895697
Gheorghiade M, Greene SJ, Butler J, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA. 2015;314(21):2251–62. https://doi.org/10.1001/jama.2015.15734 .
doi: 10.1001/jama.2015.15734
pubmed: 26547357
Lam CSP, Giczewska A, Sliwa K, et al. Clinical outcomes and response to vericiguat according to index heart failure event: insights from the VICTORIA Trial. JAMA Cardiol. 2021;6(6):706–12. https://doi.org/10.1001/jamacardio.2020.6455 .
doi: 10.1001/jamacardio.2020.6455
pubmed: 33185650
Ezekowitz JA, O’Connor CM, Troughton RW, et al. N-terminal Pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study. JACC Heart Fail. 2020;8(11):931–9. https://doi.org/10.1016/j.jchf.2020.08.008 .
doi: 10.1016/j.jchf.2020.08.008
pubmed: 33039447
Ezekowitz J, Alemayehu W, Edelmann F, et al. Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial. Eur J Heart Fail. 2024. https://doi.org/10.1002/ejhf.3179 .
doi: 10.1002/ejhf.3179
pubmed: 38606657
Lam CSP, Pina IL, Zheng Y, et al. Age, sex, and outcomes in heart failure with reduced EF: insights from the VICTORIA trial. JACC Heart Fail. 2023;11(9):1246–57. https://doi.org/10.1016/j.jchf.2023.06.020 .
doi: 10.1016/j.jchf.2023.06.020
pubmed: 37565973
Pieske B, Maggioni AP, Lam CSP, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017;38(15):1119–27. https://doi.org/10.1093/eurheartj/ehw593 .
doi: 10.1093/eurheartj/ehw593
pubmed: 28369340
pmcid: 5400074
Armstrong PW, Lam CSP, Anstrom KJ, et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial. JAMA. 2020;324(15):1512–21. https://doi.org/10.1001/jama.2020.15922 .
doi: 10.1001/jama.2020.15922
pubmed: 33079152
Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial. Circulation. 2021;143(4):326–36. https://doi.org/10.1161/CIRCULATIONAHA.120.051783 .
doi: 10.1161/CIRCULATIONAHA.120.051783
pubmed: 33081531
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303 .
doi: 10.1056/NEJMoa1911303
pubmed: 31535829
Chen C, Lv J, Liu C. Vericiguat in patients with heart failure across the spectrum of left ventricular ejection fraction: a patient-level, pooled meta-analysis of VITALITY-HFpEF and VICTORIA. Front Endocrinol (Lausanne). 2024;15:1335531. https://doi.org/10.3389/fendo.2024.1335531 .
doi: 10.3389/fendo.2024.1335531
pubmed: 38524633
Agency EM. VERQUVO® (vericiguat): EU summary of product characteristics. 2021.
Kang C, Lamb YN. Vericiguat: a review in chronic heart failure with reduced ejection fraction. Am J Cardiovasc Drugs. 2022;22(4):451–9. https://doi.org/10.1007/s40256-022-00538-5 .
doi: 10.1007/s40256-022-00538-5
pubmed: 35624347
Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021;128(10):1421–34. https://doi.org/10.1161/CIRCRESAHA.121.318172 .
doi: 10.1161/CIRCRESAHA.121.318172
pubmed: 33983838
Olivella A, Almenar-Bonet L, Moliner P, et al. Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode. ESC Heart Fail. 2024;11(2):628–36. https://doi.org/10.1002/ehf2.14647 .
doi: 10.1002/ehf2.14647
pubmed: 38158630
Forman DE, Maurer MS, Boyd C, et al. Multimorbidity in older adults with cardiovascular disease. J Am Coll Cardiol. 2018;71(19):2149–61. https://doi.org/10.1016/j.jacc.2018.03.022 .
doi: 10.1016/j.jacc.2018.03.022
pubmed: 29747836
pmcid: 6028235
Cacciatore S, Spadafora L, Landi F. Orthostatic hypotension in elderly: do you measure orthostatic and clinostatic blood pressure? Heart Vessels Transplant. 2022;4:164–7. https://doi.org/10.24969/hvt.2022.349 .
doi: 10.24969/hvt.2022.349
Unlu O, Levitan EB, Reshetnyak E, et al. Polypharmacy in older adults hospitalized for heart failure. Circ Heart Fail. 2020;13(11): e006977. https://doi.org/10.1161/CIRCHEARTFAILURE.120.006977 .
doi: 10.1161/CIRCHEARTFAILURE.120.006977
pubmed: 33045844
pmcid: 8819498
Kang DW, Kang SH, Lee K, et al. Comparative efficacy of vericiguat to sacubitril/valsartan for patients with heart failure reduced ejection fraction: systematic review and network meta-analysis. Int J Cardiol. 2024;400: 131786. https://doi.org/10.1016/j.ijcard.2024.131786 .
doi: 10.1016/j.ijcard.2024.131786
pubmed: 38242507
Balestrieri G, Sciatti E, D’Isa S, D’Elia E, Senni M. Heart failure therapy: the fifth card. Eur Heart J Suppl. 2023;25(Suppl B):B140–3. https://doi.org/10.1093/eurheartjsupp/suad099 .
doi: 10.1093/eurheartjsupp/suad099
pubmed: 37091657
pmcid: 10120986
Boettcher M, Thomas D, Mueck W, et al. Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects. Eur J Clin Pharmacol. 2021;77(4):527–37. https://doi.org/10.1007/s00228-020-03023-7 .
doi: 10.1007/s00228-020-03023-7
pubmed: 33125516
Carla Recupero SC, Marco B, Anna MM, Francesco L. Multidisciplinary care for patients with cardiac amyloidosis: a lesson from the 2023 American College of Cardiology Expert Consensus. Heart Vessels and Transplant. 2023;11:78. https://doi.org/10.24969/hvt.2023.388 .
doi: 10.24969/hvt.2023.388